CompletedPhase 2NCT05025241
An Open-Label Study of Oral NNZ-2591 in Phelan-McDermid Syndrome (PMS-001)
Studying Phelan-McDermid syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Neuren Pharmaceuticals Limited
- Principal Investigator
- James ShawNeuren Pharmaceuticals
- Intervention
- NNZ-2591(drug)
- Enrollment
- 18 enrolled
- Eligibility
- 3-12 years · All sexes
- Timeline
- 2022 – 2023
Study locations (4)
- Rush University Medical Center, Chicago, Illinois, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Boston Children's Hospital, Boston, Massachusetts, United States
- Texas Children's Hospital, Houston, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05025241 on ClinicalTrials.govOther trials for Phelan-McDermid syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07281079A Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid SyndromeNeuren Pharmaceuticals Limited
- RECRUITINGNANCT07014020RB001 Gene Therapy Study in Children With SHANK3-related Phelan McDermid Syndrome (PMS)Peking University First Hospital
- RECRUITINGPHASE1, PHASE2NCT06662188JAG201 Gene Therapy Study in Children & Adults With SHANK3 HaploinsufficiencyJaguar Gene Therapy, LLC
- ACTIVE NOT RECRUITINGNCT02461420Mapping the Genotype, Phenotype, and Natural History of Phelan-McDermid SyndromeBoston Children's Hospital